J&J division buys medical device maker
J&J Makes a $16.6 Billion Bet on Heart Pumps to Lift Medical-Device Sales - WSJ
Johnson & Johnson Will Break Itself Up Into Two Companies - The New York Times
Johnson & Johnson to split into two companies | Business
J&J Becomes the Newest Competitor in the LAA Space
Medical Devices Products | Johnson & Johnson
Johnson & Johnson to split into 2 public companies : NPR
Medical Device Sales Overview Guide: Johnson & Johnson
J&J splits off consumer health division | BioWorld
Johnson & Johnson MedTech acquires heart implant company Laminar for $400m - Medical Device Network
Johnson & Johnson Medical Devices Companies fait l'acquisition d'Orthotaxy afin de développer la nouvelle génération de plateforme de chirurgie robotique assistée pour l'orthopédie.
J&J medical devices and diagnostics sales by franchise 2020-2022 | Statista
J&J's pipeline includes 30 'major' medical devices and a surgical robot - MassDevice
Johnson & Johnson Medical Devices Companies: Reimagining the patient journey in a digital era - Source
Bayer Executive Joins Johnson & Johnson as CIO - WSJ
Résultats : J&J se redresse avant une année charnière
J&J to buy cardio technology company Abiomed for $16.6B - The San Diego Union-Tribune
Le sous-traitant Jabil reprend 14 sites de Johnson & Johnson - VIPress.net
J&J to restructure orthopedic business after medical device sales miss | Reuters
Johnson and Johnson Medical Devices Companies | HT Medical Devices
Johnson and Johnson Medical Devices Companies | HT Medical Devices
J&J says it will split into two companies in 2022
Name change for Johnson & Johnson division as they embrace MedTech — Connect Macquarie Park Innovation District
J&J is latest big pharma, device company to call it splits with consumer health - MedCity News
:max_bytes(150000):strip_icc()/GettyImages-1164571110-5aac4eab835f43658d1daaaa8fff9675.jpg "J&J Beats Profit Estimates on Pharmaceutical, Medtech Sales as COVID-19 Shot Revenue Slows")
J&J Beats Profit Estimates on Pharmaceutical, Medtech Sales as COVID-19 Shot Revenue Slows
État-major : Johnson & Johnson Medical Devices
